Estrogen/progestin extended release - Lyndra Therapeutics
Alternative Names: LYN-064; Progestin/estrogen extended release - LyndraLatest Information Update: 02 Nov 2022
Price :
$50 *
At a glance
- Originator Lyndra
- Class Combined oral contraceptives; Hormonal contraceptives; Hormonal replacements
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pregnancy
Most Recent Events
- 17 Oct 2022 Estrogen/progestin extended release - Lyndra Therapeutics is available for licensing as of 17 Oct 2022. https://lyndra.com/
- 17 Oct 2022 Lyndra’s in-licenses patents that broadly covers the transformative LYNX™ drug delivery platform from Massachusetts Institute of Technology and Brigham & Women’s Hospital (Lyndra website, October 2022).
- 17 Oct 2022 Lyndra has patents pending for LYNX™ drug delivery platform worldwide (Lyndra website, October 2022)